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Recent evidence has shown that CD56bright NK cells, a subset of NK cells abundant in lymph nodes, may
have an immunoregulatory function. In multiple sclerosis (MS), expansion of CD56bright NK cells has been
associated to successful response to different treatments and to remission of disease during pregnancy;
how whether they exert immunoregulation in physiologic conditions and whether this is impaired in MS
is not known. We dissected the immunoregulatory role of CD56bright NK cells function in healthy subjects
(HS) and compared it with that of untreated MS subjects or patients with clinically isolated syndrome
suggestive of MS (CIS). We found that CD56bright NK cells from HS acquire, upon inﬂammatory cues, the
capability of suppressing autologous CD4þT cell proliferation through direct cytotoxicity requiring
engagement of natural cytotoxicity receptors (NCRs) and secretion of granzyme B. CD56bright NK cells
from patients with MS/CIS did not differ in frequency and share a similar phenotype but displayed a
signiﬁcantly lower ability to inhibit autologous T cell proliferation. This impairment was not related to
deﬁcient expression of NCRs or granzyme B by CD56bright NK cells, but to increased HLA-E expression on
T cells from MS/CIS subjects, which could enhance the inhibitory effect mediated by NKG2A that is
homogeneously expressed on CD56bright NK cells. The defect in controlling autologous T cells by
CD56bright NK cells in MS/CIS might contribute to the excess of autoimmune response that is associated to
disease development.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In recent years, the horizon of innate immune cells has been
redesigned with the identiﬁcation of innate lymphoid cells (ILC).
ILC are now regarded as the innate, more phylogenetically ancient
mirror of T cells and thus, based on transcription factors and cy-
tokines they produce, ILC are divided in subfamilies similar to Tva, Italy.
ccelli).
nuscript.
Ltd. This is an open access article uhelper cell subsets [1]. However, whether ILC include the innate
correlate of T regulatory cell subsets has not been clariﬁed yet.
Natural killer (NK) cells are type 1 ILC innate cells with promi-
nent antitumoral and antiviral functions, which they exert through
direct cytotoxicity. NK cells express activating receptors, which
bind non HLA-speciﬁc ligands [2,3] and inhibitory receptors [4,5]
which mainly bind to autologous HLA class I molecules, thus pre-
venting them to attack healthy, autologous cells. Human NK cells
can be divided into functionally distinct subsets, based on the levels
of CD56 and of many other receptors crucial to carry out their
effector functions. Most circulating NK cells are CD56dim CD16þ,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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kines following speciﬁc recognition of their targets [6e8]. By
contrast, CD56bright NK cells, which are the predominant NK cell
subset in peripheral lymphoid organs, are CD16-/low, KIR-,
NKG2Aþ, and are known to produce large amounts of cytokines but
to acquire cytotoxicity only after prolonged activation [6,7].
We previously showed that IL-27-stimulated CD56bright NK cells
suppress autologous CD4þ T cell proliferation [9] and, more
recently, Morandi and coauthors showed that CD56bright NK cells, in
presence of autologous CD4þ T cells, release adenosine that de-
creases T cell proliferation [10]. However, the triggers and mecha-
nisms of such immunosuppressive function, and whether
CD56bright NK cells may be the counterpart of T regulatory cells
within the ILC compartment, are still to be elucidated.
Defects in regulatory cell populations of the adaptive immune
system, and particularly regulatory T cells (Tregs) have been linked
to the generation of autoimmune responses. In particular, impair-
ment in Tregs, such as natural Tregs, induced Tregs or T regulatory
cells type 1 (Tr1 cells) may link to the deregulated immune acti-
vation which leads to multiple sclerosis (MS), an autoimmune
disease of the central nervous system (CNS) [11]. Recent clinical
evidence suggests that CD56bright NK cells might also be able to
counteract autoimmune responses in the CNS. In this context,
higher numbers of CD56bright NK cells have been observed in sub-
jects with MS treated with interferon-beta, as well as MS patients
during pregnancy, a condition associated to remission of disease
activity [12,13]. More importantly, the efﬁcacy of the anti-CD25
monoclonal antibody, daclizumab, in MS was directly linked to an
increase in the number of circulating CD56bright NK cells [14]. In
patients treated with daclizumab, there was a direct correlation
between an increase of CD56bright NK cells and reduction in the
number of active lesions at Magnetic Resonance Imaging (MRI).
This was linked to an increased availability of IL-2, not binding to T
cells, that could activate CD56bright NK cells through the
intermediate-afﬁnity receptor [15]. CD56bright NK cells from
daclizumab-treated patients acquired a cytotoxic effect towards
autologous T cells that was mediated by the lytic enzyme granzyme
K [14,16].
However, it is not known whether CD56bright NK cells exert
relevant regulatory functions in physiologic conditions, to what
extent such function is important to prevent excess of immune
activation, and whether the function of CD56bright NK cells is
impaired in MS. Accordingly, the aim of this study was to assess the
possible regulatory function of CD56bright NK cells in healthy people
and in patients with MS/CIS.
2. Material and methods
2.1. Study design and population
We based our estimate of the sample size required for the study
from our previous study with IL-27 stimulated CD56bright NK cells,
wherewe observed amean suppression of Tcell proliferation¼ 46%
with a SD¼ 2. To observe a similar suppressor function of CD56bright
NK cells after IL-12 and IL-15, in HS, with a power ¼ 0.90 and a
signiﬁcance level ¼ 0.05, we needed a sample size of N ¼ 4. To
detect a 30% reduction in the suppressor function of CD56bright NK
cells from CIS/MS compared to HS, we needed a sample size N ¼ 8.
Therefore, we planned to enroll 10 HS and 10 MS or CIS patients.
PBMCs were isolated through Ficoll Paque centrifugation. In
some cases, PBMCs were frozen in Fetal Calf Serum (FCS) 90% plus
dimethyl sulfoxide (DMSO) 10%. We enrolled a total number of 22
patients with relapsing-remitting MS or CIS (MS/CIS patients) in
the study. F/M ratio was 14/8, mean age at enrolment (standard
deviationSD) was 33.04 (9.5) years, mean time after ﬁrstsymptom suggestive of MS (SD)was 4.9 (7.2) years (not available for
one patient). None of the patients was under treatment with dis-
ease modifying drugs nor steroids at the time of sampling and all
had been untreated for at least one month before blood sampling.
Twenty-one healthy donors, female/male ratio 11/10, mean
age¼ 35.00 years (9.9), donated peripheral blood. In addition, buffy
coats/leukopaks (HS) from anonymous blood donors were
employed. The amount of peripheral blood drawn from patients or
HS for the study was 70 ml.
Experiments were carried out in two laboratories. For experi-
ments carried out at the Brigham andWomen's Hospital, peripheral
blood leukopak cells were obtained from Children's Hospital, Bos-
tonMA. The leukopak cells are obtained at the time of routine blood
donation in which subjects provide written consent to have blood
drawn. These procedures are in accordance with the Children's
Hospital Institutional Review Board. Peripheral blood leukopak
cells were analyzed in the laboratory at the Brigham and Women's
Hospital that is approved by the institutional review board at
Brigham and Women's hospital for the study of human blood. For
experiments carried out at the University of Genova, peripheral
blood (HS, MS/CIS patients) was obtained after patients had pro-
vided their informed consent. The study was approved by the
Ethical Committee of IRCCS Azienda Ospedaliera Universitaria San
Martino-IST (Protocols N. 106/11 and 190/12). Buffy coats (HS) from
anonymous blood donors were obtained from the blood bank of
IRCCS San Martino IST.
2.2. Cell sorting and ﬂow cytometry
For cell sorting and ﬂow cytometry, the following commercially,
anti-human antibodies were used: CD56 (Biolegend HCD56 PE/Cy7,
APC), CD56 (Biolegend MEM-188 PE/Cy7) (Beckman Coulter IgG1
PC7), CD3 (Biolegend UCHT1, Paciﬁc Blue, FITC), CD16 (BD 3G8 IgG1
Per CP-Cy 5.5, APC), CD25 (BD IgG1 Brillant Violet 421), CD25
(Biolegend BC96 APC/Cy7), CD107a (Biolegend, H4A3 IgG1 PE),
CD69 (Biolegend FN30 PE), Granzyme B (BD Pharmigen GB11 IgG1
FITC), anti-CD4 (Biolegend clone SK3 PerCP), anti-HLA-E (Biolegend
clone 3D12 IgG1 primary antibody).
Primary anti-NKG2A (Z199 IgG2b), anti-KIRs (AZ158, IgG2a;
XA141 and Y249, IgM), anti-NCRs (aNKp30: AZ20, IgG1; aNKp44:
Z231, IgG1; aNKp46: BAB281, IgG1) mAbs, produced in our labo-
ratory (Department of Experimental Medicine, University of Gen-
ova), were used in combination with secondary anti-mouse IgG1,
IgM, IgG2a PE, IgG2b FITC (Southern Biotechnology) and IgG2a APC
(Jackson Immunoresearch) conjugated antibodies. All the primary
antibodies used were produced in AM laboratory. Cell viability was
evaluated with 7-AAD (Cell Viability Solution BD Biosciences). For
quantiﬁcation of the number of antibodies bound per cell (ABC),
cells were stainedwith the primary antibody anti-NCRs or anti-HLA
E and secondary conjugated PE antibody. Then PE ﬂuorescence
quantiﬁcation kit (QuantiBRITE, Becton Dickinson) was used for a
ﬂow cytometric estimation for antibodies bound per cell. Brieﬂy,
when a QuantiBRITE PE tube is run at the same instrument settings
as the assay, the mean ﬂuorescent intensity of the FL2 axis can be
converted into the number of PE molecules bound per cell. With
this method it is possible to create a standard curve to calculate the
number of antibodies bound per cell (ABC) and consequently, the
receptor number present on the cell surface.
In order to assess the intracellular content of granzyme B, CD4þ
cells and pre-activated CD56bright NK cells, alone or together, were
cultured overnight in presence of anti-CD3/anti-CD28 beads (Life
Technologies). Cells were then washed, stained for surface
expression of CD4 and CD56, ﬁxed and permeabilized (BD cytoﬁx/
cytoperm kit) and ﬂuorescent anti-human granzyme B antibody
was added [16]. Intracellular content of granzyme B in CD4þ T cells
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in CD56bright NK cells alone vs CD56bright NK cells cultured with
CD4þ T cells was analyzed with the Student's t-test.
Cells were sortedwith a BD FACS Aria cell sorter. Flow cytometry
data were acquired through a BD FACS Canto II. Analysis of ﬂow
cytometry data was performed with Flow Jo version 8 for Macin-
tosh and version 7 for Windows.
2.3. Isolation of NK cells
NK cells were negatively isolated from fresh or frozen PBMCs
(Miltenyi human NK cells isolation kit); NK cells were divided into
7-AADnegative/CD3-CD56bright and 7-AADnegativeCD3-CD56dim NK
cells by cell sorting. We chose to sort NK cell subsets based on the
expression of CD56 only in order to avoid triggering or masking
receptors involved in NK cell functions. Purity of NK cells was
assessed by ﬂow cytometry after cell sorting and was equal to 99%.
2.4. Isolation of CD4þ T cells
CD4þ T cells were negatively isolated from fresh or frozen
PBMCs (Miltenyi human CD4þ T cell isolation kit). Purity of CD4þ T
cells after isolationwas checked by ﬂow cytometry to be above 95%.
CD4þ T cells were frozen in fetal calf serum (FCS) 90% plus dimethyl
sulfoxide (DMSO) 10%, during the 3-days activation period of NK
cell subsets detailed below.
2.5. Activation of NK cells and suppression assay
NK cell subsets were cultured in fresh medium alone or with
human recombinant IL-12 (R and D Systems, 10 ng/ml) plus human
recombinant IL-15 (R and D systems, 100 ng/ml) for 72 h. To study
gene expression, the culture was stopped after 24 h. Activated
living (7-AAD negative) NK cells were resorted and cultured for 5
days in presence of sorted living (7-AAD negative) autologous CD4þ
T cells at a 1:1 ratio in presence of anti-CD3 anti-CD28 activation
beads (Life Technologies); controls included activating beads plus
CD4 þ T cells alone or activating beads plus NK cells alone. Alter-
natively, living NK and CD4þ T cells were counted through optical
microscopy in presence of Trypan blue and cocultured as previously
detailed. To suppress the effect of granzyme B, the speciﬁc inhibitor
Z-AAD-CMK (Merck Millipore) was added to the cultures at
concentration ¼ 10 nM.
Proliferation of T cells was assessed by incorporation of 3H
thymidine or with the CyQUANT Cell Proliferation Assay Kit, that
measures the DNA content in cultures (Life Technologies), sub-
tracting the measure obtained from CD56bright NK cells cultured in
absence of T cells. Proliferation of CD56bright NK cells was not
observed in control wells when measured by incorporation of 3H
thymidine.
In order to compare the suppressor function of CD56bright NK
cells from HS and MS/CIS patients, paired experiments (one or two
MS/CIS subjects, one or two HS) were carried out.
2.6. Degranulation assay
For cytotoxicity assay, NK cell subsets and autologous CD4þ T
cells were cocultured in presence of anti-CD3 anti-CD28 activation
beads, as described above. Cultures were stopped after 24 h to
assess degranulation of NK cells and after 5 days to assess death of
CD4þT cells. For degranulation assays, anti-CD107a antibody and
brefeldin A (Sigma) were added to the wells, respectively 4 and 3 h
before stopping the culture. Cells were then washed and stained
with ﬂuorescent antibodies (anti-CD3, anti-CD56, and anti-CD16)
for surface markers. Expression of CD107a on NK cells culturedalonewas used as negative control. For analysis of T cell death, the %
of 7-AAD-positive, CD3-positive cells was assessed.
2.7. Study on gene expression
Total RNA was isolated from cell pellets using RNAeasy Mini Kit
(Qiagen). First-strand cDNA synthesis was performed for each RNA
sample from 0.5 to 1 mg of total RNA using Taqman reverse-
transcription reagents (Life Technologies). For experiments car-
ried out at the Brigham and Women's hospital laboratory, cDNA
was ampliﬁed using sequence-speciﬁc primers and real-time PCR
mix (Applied Biosystems) on ABI 7500 cycler. For experiments
carried out at University of Genova, real-time PCR was performed
using a LightCycler 480 (Roche) in presence of SYBR Green I Master
mix (Roche), according to the manufacturer's instruction and of the
following primers, synthesized by Tib Molbiol (Genova, Italy), were
used: human granzyme A: forward primer 50-TTAACCCTGT-
GATTGGAATGAAT-30, reverse primer 50-AGGGCTTCCAGAATCTC-
CAT-30; human granzyme B, forward primer 50-
AGATGCAACCAATCCTGCTT-30, reverse primer 50-CATGTCCCCC-
GATGATCT -30 human granzyme H forward primer 50-
GCAGCCTTCCTGAGAAAATG-30, reverse primer 50-CCCCGAT-
GATCTCCTCTGT-30; human granzyme K: Forward primer 50-
ATCTGGAACCAAATGCAAGG-30, Reverse primer 50-
TCTCGCAGGGTGTCAGAAG; human granzymeM forward primer 50-
GCGTGTCTTCACTGCTGGT-30, reverse primer 50-ATGATCTGGGTCC-
CAAAGg-30; human perforin forward primer 50-CCGCTTCTCTA-
TACGGGATTC, -30 reverse primer GCAGCAGCAGGAGAAGGA-30;
human Fas ligand: forward primer 50-TGGGGATGTTTCAGCTCTTC-
30, reverse primer 50-TGTGCATCTGGCTGGTAGAC-30; human CD16
forward primer 50-GGGGGCTTTTTGGGAGTA-30, reverse primer 50-
GGTTGACACTGCCAAACCTT-30.
The human Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (forward primer 5-AGCCACATCGCTCAGACAC-30, reverse
primer 50-GCCCAATACGACCAAATCC-30) was used as housekeeping
gene to normalize the expression data. All values were expressed as
relative expression of gene of interest to the expression of GAPDH
and displayed as ratio of stimulated vs. unstimulated cells.
2.8. Receptor blocking experiments
To evaluate the possible contribution of NK cell receptors to
suppression of proliferation of autologous T cells, suppression as-
says were carried out in presence or absence of the following an-
tibodies produced in our laboratory (Department of Experimental
Medicine, University of Genova): anti-NKp30 (F252, IgM), anti
NKp44 (KS38, IgM), anti-NKp46 (KL247, IgM), anti DNAM-1 (F5,
IgM) anti NKG2D, (BAT221 IgG1), anti HLA-I (A6136, IgM). The anti-
HLA I antibody was allowed to bind to CD4þ T cells before adding
CD56bright NK cells, while anti-NKp30, anti-NKp44, anti-NKp46,
anti-NKG2D and anti-DNAM-1 were added to the co-cultures
since the beginning. To study the effects of blocking HLA-class I
in CD4þ T cells from HS compared to MS/CIS patients, paired ex-
periments (one or twoMS/CIS patients, one or two HS)were carried
out. F252, F5 and BAT221 mAbs were kindly provided by Dr. D.
Pende from IRCCS San Martino-Ist, Genova, Italy. KL247 and KS38
mAbs were kindly provided by Prof. S. Parolini from University of
Brescia, Italy.
2.9. Statistics
Sample sizewas calculatedwith the PASS 11 software. Datawere
analyzed with Graph Pad Prism 6. The following statistic tests were
used: two tailed Wilcoxon matched-pairs test, Student t-test,
Mann-Whitney test. A P  0.05 was considered signiﬁcant.
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3.1. IL-12 and IL-15 induce immunoregulatory cytotoxic CD56bright
NK cells
NK cells were negatively isolated from fresh or frozen peripheral
blood mononuclear cells (PBMCs) and NK cell subsets were sorted
by the expression of CD56. The phenotype of CD56bright
(Supplementary Fig. 1) and CD56dim (not shown) NK cell subsets
was assessed by ﬂow cytometry after cell sorting.
We chose to activate CD56bright NK cells with IL-12 and IL-15,
two antigen presenting cells (APC)-derived, proinﬂammatory cy-
tokines whose levels are increased in MS and having a pivotal role
in NK activation [17e19]. After activation with IL-12 and IL-15, the
two CD56bright and CD56dim NK cell subsets were cocultured for 5
days with autologous CD4þ T cells in presence of a T cell speciﬁc
stimulus, represented by anti-CD3/anti-CD28 beads. We observed
that CD56bright, but not CD56dim NK cells signiﬁcantly suppressed
autologous CD4þ T cells proliferation (P ¼ 0.002) (Fig. 1a). We did
not observe signiﬁcant suppression of proliferation of autologous T
cells when co-culturing themwith unstimulated CD56bright NK cells
(Supplementary Fig. 2).
We investigated whether the decreased proliferation of CD4þ T
cells in presence of CD56bright NK cells was due to increased cell
death. We measured by ﬂow cytometry the percentage of dead (7-
aminoactinomycin Dþ)(7-AADþ) T cells in presence of activated
CD56bright and CD56dim NK cells after 5 days of coculture with anti-
CD3/anti-CD28 beads and observed a signiﬁcantly higher % death of
CD4þ T cells in presence of CD56bright NK cells (P ¼ 0.03), but not
CD56dim NK cells (P ¼ ns) (Fig. 1b).
We postulated that CD56bright NK cells-mediated cytotoxicity
could be responsible for increased death of autologous T cells.
Therefore, we studied degranulation of CD56bright NK cells (as
measured by expression of CD107a on NK cell surface) after one day
of coculture with autologous CD4þ T cells and anti-CD3/anti-CD28
beads, in comparison with that of CD56dim NK cells. We observed a
signiﬁcantly higher degranulation of CD56bright NK cells (Fig. 1c,
central panel and Fig. 1d) compared to CD56dim NK cells (Fig. 1c, left
panel and Fig. 1d). CD56bright NK cells did not degranulate in
presence of unstimulated CD4þ T cells, thus indicating that this NK-
mediated effector functionwas speciﬁc for CD4þ T cells undergoing
activation (Fig. 1c, right panel and 1e). To assess whether a cell-to-
cell contact cytotoxic mechanism was involved in the suppressive
function of CD56bright NK cells, we assessed suppression in contact
or transwell experimental condition, and found that transwell
coculture abrogated the suppression of autologous CD4þ T cell
proliferation by CD56bright NK cells (Fig. 1f). These results suggest
that a direct cell-to-cell interaction is required to allow the sup-
pressive function of CD56bright NK cells against autologous activated
T cells.
3.2. Natural cytotoxicity receptors are required for CD56bright
suppressive function
In order to assess which receptors trigger the suppressive
function of CD56bright NK cells against autologous activated T cells,
we performed proliferation assays in presence of antibodies
masking the main non HLA-speciﬁc activating NK receptors (nat-
ural-killer group 2, member D- NKG2D, natural cytotoxicity re-
ceptors -NCRs: NKp30, NKp44, NKp46, DNAX Accessory Molecule-
1- DNAM-1) or blocking HLA class I molecules in T cells. We chose
not to block the activating CD16 receptor because in our in vitro
culture system, a role of CD16 is unlikely, since the receptor is
involved in antibody-dependent cell-mediated cytotoxicity and
there were no antibodies added to the co-culture (except for thosebound to the magnetic beads for stimulation of T cells: these beads-
associated mAbs are unable to bind to CD16) [20]. We found that
the suppressive function of CD56bright NK cells was reverted by
addition of a mix of anti-NCR antibodies (P ¼ 0.0005), while
blocking other activation receptors (including NKG2D and DNAM-
1) did not restore T cell proliferation (Fig. 2a). Masking the HLA
molecules on Tcells did not increase signiﬁcantly the cytotoxicity of
NK cells towards T cells (Fig. 2a). To determine what NCRs were
speciﬁcally involved in NK-T interaction, we performed suppression
assays in presence of antibodies blocking single NCRs and observed
that anti-NKp30 and anti-NKp46 antibodies, but not anti-NKp44
antibody, reverted CD56bright suppressor function (Fig. 2b). In
addition, we evaluated the number of NCRs expressed in basal
conditions or upon exposure to IL-12 and IL-15 by CD56bright NK
cells and found that NKp30 and NKp44, but not NKp46, were
upregulated after cytokines-mediated activation (Fig. 2c). We did
not observe upregulation of the NKp46 receptor that had already
high baseline expression in CD56bright NK cells, consistently towhat
is known from the literature [21,22].
3.3. Release of granzyme B by CD56bright NK cells is involved in
cytotoxicity of autologous CD4þ T cells
To dissect cytotoxicity of CD56bright NK cells, we evaluated, by
real-time PCR, changes in transcription of genes encoding gran-
zyme proteins, perforin, Fas ligand, the Fc-gamma receptor CD16,
and theTNF-related apoptosis-inducing ligand (TRAIL), all of which
are involved in NK-mediated cytolytic activity. We observed that IL-
12 and IL-15 upregulated exclusively mRNA for granzyme B in
CD56bright NK cells while other genes were not induced (Fig. 3a).
Then, we evaluated the intracellular content of granzyme B in CD4þ
T cells and CD56bright NK cells cultured separately or together,
similarly to what previously described by Jiang and coauthors [16].
In CD4þ T cells/CD56bright NK cells cocultures, the intracellular
content of granzyme B increased in CD4þ T cells and decreased in
CD56bright NK cells, compared to CD4þ T cells or CD56bright NK cells
cultured alone, thus suggesting a transfer of granzyme B from NK
cells to T cells during coculture (Fig. 3b).
Accordingly, inhibition of granzyme B function by Z-Ala-Ala-
Asp-chloromethylketone (Z-AAD-CMK) signiﬁcantly decreased the
suppressive function of CD56bright NK cells (Fig. 3c). Taken together,
these three observations suggest that transfer of granzyme B me-
diates the cytotoxic function of CD56bright NK cells towards autol-
ogous activated CD4þ T cells.
3.4. Suppression of autologous T cells by CD56bright NK cells is
impaired in untreated MS individuals
Next, we sought to address whether CD56bright NK cells fromMS
subjects could suppress autologous CD4þ T cell proliferation as
efﬁciently as NK cells from HS.
We decided to focus our analysis on untreated MS/CIS patients,
rather than on treated MS patients, in order to assess whether a
defect in the regulatory function of CD56bright, which might
contribute to disease development, is found in MS patients
compared to healthy control.
We ﬁrst observed that untreated MS patients and subjects with
clinically isolated syndrome suggestive of MS (CIS) display pro-
portion of CD56bright/CD56dim NK cells similar to those of HS
(Fig. 4a). Subsequently, we assessed the capability of cytokines
stimulated CD56bright NK cells from untreated MS/CIS patients to
suppress autologous T cell proliferation. Interestingly, we observed
that the suppression of T cell proliferation by CD56bright NK cells
fromuntreatedMS/CIS patients was signiﬁcantly lower than that by
CD56bright NK cells from HS (Fig. 4b).
Fig. 1. CD56bright NK cells suppress autologous CD4þ T cell proliferation through direct cytotoxicity. a. Plots showing suppression of autologous CD4þ T cell proliferation by
CD56bright NK cells (Wilcoxon, P ¼ 0.002) but not CD56dim NK cells (Wilcoxon, P¼ NS). There is a signiﬁcant difference among the suppressive function of the two NK cell subsets
(Wilcoxon, P ¼ 0.03). Results are shown as mean ± standard error of the mean. N ¼ 11 healthy subjects. b. Percentage of dead (7-AAD positive) CD4þ T cells in presence of CD56bright
NK cells (Wilcoxon, P ¼ 0.03) and in presence of CD56dim NK cells (Wilcoxon, P¼ NS) evaluated by ﬂow cytometry. Results are shown as mean ± standard error of the mean. N ¼ 6
experiments. c. Representative FACS plots showing degranulation of CD56dim in presence of stimulated autologous CD4þ T cells (in blue, left), as compared with degranulation of
CD56bright NK cells (in blue, center). Right panel shows degranulation of CD56bright NK cells in presence of non-activated autologous CD4þ T cells (in blue). Contour plots in red: same
NK cell subset cultured in absence of autologous CD4þ T cells. d. Cumulative plots showing percentage of CD107aþ (degranulating) CD56bright NK cells compared to percentage of
CD107a þ CD56dim NK cells co-cultured with autologous CD4þ T cells (Wilcoxon test, P ¼ 0.01). Results are shown as mean ± standard error of the mean. N ¼ 9 healthy subjects. e.
Plots showing percentage of degranulating CD56bright NK cells in presence of activated (by CD3/CD28 molecules) and non activated CD4þ T cells Paired t-test, P ¼ 0.02. Results are
shown as mean ± standard error of the mean. N ¼ 3 healthy subjects. f. Suppressive function of CD56bright NK cells in presence of cell-to-cell contact (CD56bright C) or in transwell
(CD56bright T) experimental condition. Results are shown as mean ± standard error of the mean. Paired t-test, P ¼ 0.04. N ¼ 3 healthy subjects.
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similar cell surface phenotype
Next, we sought to exclude that a defective suppressive function
by CD56bright NK cells isolated from MS/CIS patients was due to a
change in their phenotype, considering the possibility that
CD56bright NK cells could include a fraction of activated CD56dim NK
cells characterized by an up-regulation of this marker [23]. There-
fore, we evaluated other typical markers deﬁning the phenotype of
CD56bright NK cells inMS/CIS patients and HS. Expression of NKG2A,
KIRs and CD16, as well as of the activation markers CD25 and CD69,
was not different in CD56bright NK cells from untreated MS/CIS
patients compared to HS (Fig. 5a, Fig. 5c: gating strategy). Expres-
sion of the same markers did not differ in CD56dim NK cells fromMS/CIS and HS (data not shown).
We subsequently checked by ﬂow cytometry whether the
defective suppressor function of CD56bright NK cells from MS/CIS
subjects was due to a decreased expression of NCRs. Not only did
we not observe a decreased expression of NCRs, but we found an
increased expression of NKp30 and NKp46 in CD56bright NK cells
from untreated MS/CIS patients (Fig. 5b). Transcription of the
granzyme B gene was not different in untreated MS/CIS compared
to HS (Fig. 5d).
3.6. Increased expression of HLA-E on CD4þ T cells inhibit the
regulatory function of CD56bright NK cells in MS
As no signiﬁcant differencewas detected in the NCR/granzyme B
Fig. 2. The activating receptors NKp30 and NKp46 are required for the suppressive function of CD56bright NK cells. a. Proliferation assays in presence of antibodies masking the
activating NK receptors on CD56bright NK cells (NKG2D, NCRs: NKp30, NKp44, NKp46, DNAM-1) or blocking HLA class I molecules on T cells. Every plot depicts proliferation of cells
from one subject. Mean and SEM are also displayed in the graph. Wilcoxon test, P ¼ 0.0005 for suppression in presence of anti-NCRs; no signiﬁcant differences with other blocking
antibodies. N ¼ 6e12 healthy subjects. b. Proliferation assays in presence of antibodies masking single NCRs: NKp30, NKp44, NKp46. Signiﬁcant decrease of proliferation when
blocking NKp30 and NKp46 (Wilcoxon test, P ¼ 0.007 for both; N ¼ 9 subjects). c. The three activating receptors NKp30, NKp44, NKp46 were evaluated by ﬂow cytometry on basal
conditions (ex vivo) isolated and after stimulus with IL-12 and IL-15 CD56bright NK cells. The number of antibodies bound per cell (ABC) was estimated adding BD quantiBRITE PE
beads. Mann-Whitney test, P ¼ 0.02 for NKp30, P ¼ 0.008 for NKp44, P]NS for NKp46. N ¼ 16 subjects for ex-vivo isolated CD56bright NK cells, 3 subjects for stimulated CD56bright
NK cells.
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assessed whether defective suppression could be related to the T
cells themselves being less prone to NK attack. Therefore, we
addressed the possibility that this could be due to an increased
inhibitory signal generated in NK cells upon interaction with
autologus CD4þ Tcells. We found that blocking HLA class I on T cells
restored normal suppressive function of CD56bright NK cells in un-
treated CIS/MS (Fig. 6a). CD56bright NK cells sense HLA class I mol-
ecules through the inhibitory receptor NKG2A, which binds to HLA-
E [24]. We did not observe differences in the expression of NKG2A
among CD56bright NK cells from MS/CIS and from HS (Fig. 5a); in
contrast, we found an increased expression of HLA-E on T cells of
subjects with MS/CIS compared to HS (Fig. 6b).4. Discussion
The results of this work shed light on the function of the
CD56bright NK cell subset in healthy conditions and in MS. First, we
demonstrated that CD56bright NK cells are a regulatory population
controlling proliferation of CD4þ T cells through a cytotoxic
mechanism. Second, we provided evidence that such regulatory
mechanism is impaired in MS/CIS.
Immune cells with regulatory function have been identiﬁed
within the T- and B- compartments of the adaptive immune system
and comprise, among others, natural Tregs, induced Tregs, type 1
regulatory T (Tr1) cells, and Bregs. These cell types control T effector
cells through different mechanism including cytotoxicity and
release of cytokines; a defect in their function is believed to
Fig. 3. Granzyme B mediates the regulatory function of CD56bright NK cells. a. Real time PCR experiments showing increased (dark grey) of decreased (light grey) transcription of
genes related to the lytic machinery of NK cells after 3 day-stimulus with IL-12 þ IL-15. Results are shown as ratio of relative (ref gene: GAPDH) expression in stimulated CD56bright
NK cells compared to unstimulated CD56bright NK cells. Wilcoxon test, P ¼ 0.03 for granzyme B. Results are shown as mean ± SEM of at least 4 healthy subjects. b. Intracellular
content of granzyme B in CD4þ cells cultured alone or with CD56bright NK cells and in CD56bright NK cells cultured alone or in presence of CD4þ T cells, as measured by ﬂow
cytometry. Empty symbols: culture of CD4þ T cells (circle) or CD56bright NK cells (triangle) alone. Filled symbols: intracellular content of granzyme B in T cells (circle) and CD56bright
NK cells (triangle) in coculture. Paired t-test, P ¼ 0.03 for CD4þ cells and CD56bright NK cells. N ¼ 3 healthy subjects. c. Suppression of activated CD4þ T cell proliferation in absence or
presence of the granzyme B inhibitor Z-AAD-CMK. Wilcoxon test, P ¼ 0.046. N ¼ 7 healthy subjects.
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innate immune system, and particularly within the ILC family, are
much less characterized. We focused on CD56bright NK cells because
an increased number of this NK cell subset has been observed inMS
patients following successful treatments, for example with dacli-
zumab [25], and in pregnancy, a physiological condition often
associated with MS disease remission [13]. Therefore, we hypoth-
esized that these cells may contribute to maintaining immune
homeostasis and might be altered in an autoimmune disease such
as MS. CD56bright NK cells had been previously marked as “immu-
noregulatory” due to their capability of releasing large amounts of
cytokines, their lower cytotoxic potential towards cancer and virus-
infected cells and their enrichment in lymph nodes T cell area.
Others have previously shown that CD56bright NK cells can kill pre-
activated T cells [26e28]. Compared to other studies, we chose to
assess the impact of CD56bright NK cells on the proliferation ofautologous CD4þ T cells. Therefore, instead of performing a short
lasting cytotoxicity assay with pre-activated CD56bright NK cells and
T cells, we cultured CD56bright NK cells and ex-vivo isolated autol-
ogous CD4þ T cells in presence of T-cell stimulus and observed that
the presence of CD56bright NK cells markedly decreased autologous
CD4þT cell proliferation in HS. This effect was dependent on
CD56bright NK-mediated cytotoxicity against autologous T cells
undergoing activation and may indicate that the role of CD56bright
NK cells is to prevent excessive activation of CD4þ T cells. At this
stage, we do not knowwhether this effect targets speciﬁc subsets of
CD4þ Tcells including Tregs, effector cells and possibly autoreactive
cells.
We found that two activating NK receptors, the NCRs NKp30 and
NKp46, mediate the recognition and killing of autologous T cells by
CD56bright NK cells. Some NCRs ligands are unknown at this time
[29]; in this context our study suggests that ligands for such
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Fig. 4. CD56bright NK cells from untreated MS/CIS patients do not suppress autol-
ogous T cell proliferation. a. Mean ± SD of the proportion of CD56bright NK cells over
total NK cells in untreated MS/CIS patients compared to HS, as evaluated by ﬂow
cytometry in negatively isolated NK cells. Wilcoxon test, P ¼ ns. N ¼ 12 HS and 13 MS/
CIS patients. b. Suppressive function of CD56bright NK cells from untreated MS/CIS
patients towards autologous CD4þ T cells compared to suppressive function of
CD56bright NK cells towards autologous CD4þ T cells from HS, in paired experiments.
Wilcoxon test, P ¼ 0.0002. N ¼ 13 subjects with CIS or MS and 13 paired HS.
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tion, thus providing a possible mechanism tomaintain homeostasis
in healthy subjects by modulating any excess of activation. More-
over, upon IL-12 and IL-15 stimulation, we observed a signiﬁcant
upregulation of granzyme B in CD56bright NK cells, whose blockade
resulted in a signiﬁcant decrease of suppression of autologous T cell
proliferation. These data suggest that in autologous activated CD4þ
T cells/CD56bright NK cells cocultures, after NCRs engagement, a
transfer of granzyme B from NK cells to T cells may be responsible
for NK-mediated T cell death. Interestingly, killing by granzyme B
was described by Tr1 cells, that appear similar to CD56bright NK cells
in other aspects: they simultaneously secrete IFN-gamma and IL-10
[17,30] and may be induced by IL-27 [9,31].
In HS, the proinﬂammatory cytokine IL-12, which promotes
activation of the regulatory CD56bright NK cells in combinationwith
IL-15, has been shown to dampen the regulatory function of
FOXP3þ T regulatory cells [32]. Therefore, we may speculate that,
when inﬂammation occurs in HS, IL-12 is produced, and Tregs areless functional, CD56bright NK cells represent a main regulatory
subset whose role may be important to prevent excess of T cell
response. If this is the case, a defect in CD56bright NK cells-mediated
immunoregulation may be associated to the development of un-
controlled T cells responses and contribute to autoimmunity.
Accordingly, we found that in early MS/CIS subjects, CD56bright
NK cells suppressed CD4þ T cells proliferation less efﬁciently than
in HS despite similar proportion of CD56bright NK cells over total NK
cells. Defective function of CD56bright NK cells in MS/CIS was not
explained by higher baseline activation, as shown by comparable
expression of activation markers and production of granzyme B
with respect to NK cells from HS. Neither have we found a
decreased expression of NCRs involved in the suppressive function;
these were indeed upregulated, in what may be an attempt to
compensate for the lower suppressive function.
Conversely, we observed that blocking the inhibitory interaction
between the NKG2A receptor expressed by CD56bright NK cells and
its ligand HLA-E, whose surface expression on CD4þ T cells was
found higher in MS subjects compared to HS, recovers CD56bright
NK cells ability to suppress T cell proliferation in MS/CIS. This
suggests that impairment of the regulatory function of CD56bright
NK cells is due to an excess of HLA-E-mediated inhibition by acti-
vated CD4þ T cells from MS/CIS patients. Interestingly, in line with
this assumption, upregulation of HLA-E in active MS lesions and in
the CSF of MS patients has been observed [33,34]. All together these
ﬁndings may suggest an impairment of CD56bright NK cells regu-
latory functions not only in peripheral blood, but also within the
CNS of MS subjects.
Studies in the mouse model for MS, experimental autoimmune
encephalomyelitis (EAE), have provided conﬂicting results on the
role, beneﬁcial vs. detrimental, of NK cells in disease, as reviewed in
Ref. [35]. This may be related to the differences among animal and
human diseases, and to the difﬁculty to compare human andmouse
NK cell subsets: since mice NK cells do not express CD56, the
counterpart of CD56bright NK cells in mice has not been identiﬁed.
Moreover, mouse NK cells express an analogue of NKp46 as the only
NCR. With these premises, in mice, a regulatory role for NK cells
expressing NKG2A has been observed by Lu and coauthors; they
showed that blocking the interaction between NKG2A and the
murine analogue of HLA-E on T cells, Qa-1b/Qdm, enables NK cells
to control T cell activation, thereby ameliorating EAE [36], and is
associated with lysis of pathogenic T cells and decreased inﬁltration
of T cells into the CNS [37]. Others have found a NKG2D-mediated
killing of T cells by NK cells in mice [38]. In humans, Nielsen and
coauthors [26] observed cytotoxicity by CD56bright NK cells towards
activated CD4þ T cells, mainly mediated by the engagement of
NKG2D, LFA-1 and TRAIL. The authors also found that blocking
NKp46 decreased degranulation of CD56bright NK cells in presence
of activated CD4þ T cells. In the study by Nielsen and coauthors,
CD56bright NK cells were not puriﬁed by cell sorting but gated
among total NK cells cultured in presence of target T cells. Others
have found a cytotoxic mechanism of polyclonally activated NK
cells towards T cells, again relying on NKG2D [27]. Schlums and
coauthors recently described cytotoxicity of the CD56dim NK cell
subset towards autologous CD4þ T cells related to the expression of
receptors belonging to the signaling lymphocytic activation mole-
cule (SLAM) family [28]. Different from these studies, we sorted
CD56bright NK cells before cytokine-mediated stimulation. Thus we
avoided the cytokine-induced NK cell activation which is known to
result in upregulation of the CD56marker by CD56dim NK cells [23].
On the other side, the thorough two-step isolation method of a cell
population which is scarce in blood (about 1% of circulating lym-
phocytes) provided us with low numbers of cells for experimental
conditions and limited the possibility to assess degranulation of
CD56bright NK cells at multiple time-points during the NK-T
Fig. 5. Analysis for relevant cell surface molecules indicate that CD56bright NK cells from untreated MS/CIS patients and HS have similar phenotype and produce granzyme B.
a. FACS analysis for speciﬁc NK cell markers in CD56bright NK cells from HS and untreated MS/CIS. Cells were gated from total PBMCs as CD3negative/CD56bright. Results are shown as
scatter dot plots, mean ± SEM. N ¼ 4e10 HS and 4e10 untreated paired MS/CIS patients. HS vs. MS/CIS, Wilcoxon test, P¼ NS for all markers. b. Expression of the NCRs NKp30,
NKp44 and NKp46 in CD56bright NK cells from untreated MS/CIS patients compared to HS. The number of receptors per cell was assessed through ﬂow cytometry with the BD
QuantiBRITE method. Top panels show FACS histograms from one representative experiment, with blue histogram showing the mean ﬂuorescence intensity of the receptor in
CD56bright NK cells from untreated MS/CIS patient, and red histogram depicting data of the paired HS. The grey-shaded histogram represents the negative control (staining for
NKp44 in CD56dim NK cells). Bottom panels show expression of the NCRs from 12 paired HS and untreated MS/CIS patients (NKp30, NKp44), and 13 paired HS and CIS/MS patients
(NKp46). Wilcoxon test, P ¼ 0.02 for NKp30 and P ¼ 0.04 for NKp46. c. Gating strategy for cytometric analysis of NK cell subsets. d. Real-time PCR data showing expression of
granzyme B in CD56bright NK cells isolated from 9 HS and 4 untreated MS/CIS patients after 24 h of activation with IL-12 and IL-15 compared to CD56bright NK cells cultured for 24 h
without stimulus. Mann-Whitney test, P ¼ NS.
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CD56bright NK cells continuously occurs over time during the cul-
ture, may explain, in our opinion, the lower degree of NK degran-
ulation we observed compared to other studies.
The evidence that the mechanism of action of daclizumab relies,
at least in part, on the expansion of CD56bright NK cells had pointed
towards a beneﬁcial role of this cell subset. This work shows for the
ﬁrst time an impairment in NK cell-mediated immunoregulation in
untreated MS, that is attributable more to the T cells being resistant
to NK suppressive action than to intrinsic defects of the NK cellsthemselves. To conﬁrm the parallelism between CD56bright NK cells
and regulatory cells, others showed that in MS, CD4þ T cells escape
from regulation by Tregs [39].
Increasing the number of CD56bright NK cells, a major mecha-
nism of action of daclizumab in MS, appears to overcome this
defect. This is in line with what has been reported by the group of
Bielekova, which showed that daclizumab, in addition to increasing
the number of circulating CD56bright NK cells, changes their
phenotype in order to make them more cytotoxic [14,16]; we
cannot exclude that daclizumab affects also CD4þ T cells, bymaking
Fig. 6. Increased HLA-E on CD4þ T cells inhibits cytotoxicity of CD56bright NK cells
from untreated CIS/MS patients. a. Suppression of autologous CD4þ T cells prolifer-
ation by CD56bright NK cells from HS or untreated MS/CIS patients in absence or
presence of anti-HLA I antibody (paired experiments with at least one HS and one MS/
CIS patient). N ¼ 5 HS, 6 MS/CIS (without anti-HLA I antibody) and 5 MS/CIS patients
(with anti-HLA I antibody). Mann-Whitney test, P ¼ 0.004 for HS vs MS/CIS (both in
absence of anti-HLA class I antibody); P ¼ ns for HS in absence of anti-HLA class I
antibody vs MS/CIS in presence of anti-HLA class I antibody, P ¼ 0.004 for MS/CIS
patients in absence vs CIS/MS patients in presence of anti-HLA class I antibody. b.
Expression of HLA-E (ligand for NKG2A) on CD4þ T cells of untreated MS/CIS patients
compared to HS, measured by ﬂow cytometry with the BD QuantiBRITE method. ABC:
number of antibodies bound per cell. N ¼ 10 HS and 10 subjects with MS/CIS.
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with daclizumab have experienced adverse events possibly asso-
ciated to accumulation of CD56þ cells in lymph nodes or in the
breasts [40]. The ﬁndings of the present study provide new insightsabout the role of CD56bright NK cells in the regulation of immune
responses and suggest that reverting defective immunoregulation
exerted by CD56bright NK cells may be as well a potential thera-
peutic target in MS.
In conclusion, the results of our study show the possible
importance of innate immunity resident in lymph nodes in pre-
venting autoimmune responses by controlling autologous T cell
activation, and suggests that the evasion of T cells from CD56bright
NK cell control may contribute to the deregulated T cell response
observed in MS.
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